Biopharma PEG Scientific Inc.

Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine agent in clinical studies, many advances have been made in the field of mRNA therapeutic technology after nearly 30 years of development.

In recent years, the scope and application scenarios of drug conjugates, including multiple concepts such as combination medication and precise drug delivery, have continued to expand, and a variety of emerging conjugation technology concepts have...

PROTACs (Proteolysis-targeting Chimeras), which was first proposed by Crews et al in 2001, can reduce protein levels rather than inhibit protein functions by taking advantage of the natural protein cleaning system in the body.

In recent years, targeted protein degraders have entered the mainstream of drug development at a very rapid rate.

Polyethylene glycol (PEG) is a polyether compound derived from petroleum with many applications, from industrial manufacturing to medicine.

Nmerous applications of PEGs have been reported in the scientific literature over the years.

Just one dose of a new nanoparticle-based COVID-19 vaccine is enough to generate an immune response in animals, and the vaccines currently in clinical use are on track.

Among adults with overweight or obesity, once-weekly subcutaneous semaglutide plus counseling for diet and physical activity results in significantly greater weight loss at 68 weeks than once-daily subcutaneous liraglutide, according to a study published.

3D printing (3DP) technology has been repurposed to apply to pharmaceutical development, in recent years it has been used to produce tablets of personalized dosage and combine several prescriptions into one tablet.

Antibody-Drug Conjugates (ADC) is a type of anticancer drug that links a drug to cancer-targeting antibodies. The antibody detects tumor-specific proteins expressed on cancer cells and directs the cytotoxic anticancer drug towards the cancer cell.